Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China.
Dliner Bioelectrical LLC, Jiangyin, Wuxi, Jiangsu Province, PR China.
Clin Genitourin Cancer. 2017 Oct;15(5):570-576. doi: 10.1016/j.clgc.2017.05.001. Epub 2017 May 10.
Recent studies have demonstrated that the expression of long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes cancer cell proliferation, invasion, and metastasis in many tumor types, but the association between bladder cancer and MALAT1 remains unknown.
The expression of MALAT1 was tested by in situ hybridization (ISH) in 120 bladder cancer specimens. The association between MALAT1 expression and clinicopathological features and prognosis of the patients with bladder cancer was analyzed. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the relationship between the expression of MALAT1 and progression and metastasis of bladder cancer.
ISH showed that high MALAT1 expression was associated with advanced histological grade, high tumor stage, and positive lymph nodes. Kaplan-Meier survival analysis and Cox regression analysis indicated that high tumor stage, positive lymph nodes, and high MALAT1 expression were independent prognostic indicators for overall survival (OS) of patients with bladder cancer. qRT-PCR showed that the expression of MALAT1 in bladder cancer tissues was 2.85 times higher than those measured in adjacent normal tissues (P < .001). The expression of MALAT1 was 2.673 ± 0.254 in non-muscle-invasive bladder cancer and 2.987 ± 0.381 in muscle-invasive bladder cancer (P = .018). In bladder cancer specimens with positive lymph nodes, MALAT1 expression was 3.167 ± 0.297 versus 2.896 ± 0.329 in bladder cancer specimens with negative lymph nodes (P = .020).
High MALAT1 expression could serve as an independent prognostic factor for OS of patients with bladder cancer and could be considered as a potential therapeutic target of bladder cancer.
最近的研究表明，长链非编码 RNA 转移相关肺腺癌转录本 1（MALAT1）的表达促进了许多肿瘤类型中的癌细胞增殖、侵袭和转移，但膀胱癌与 MALAT1 之间的关联尚不清楚。
通过原位杂交（ISH）在 120 例膀胱癌标本中检测 MALAT1 的表达。分析 MALAT1 表达与膀胱癌患者临床病理特征和预后的关系。采用实时定量聚合酶链反应（qRT-PCR）验证 MALAT1 表达与膀胱癌进展和转移的关系。
ISH 显示，MALAT1 高表达与高级别组织学分级、高肿瘤分期和阳性淋巴结有关。Kaplan-Meier 生存分析和 Cox 回归分析表明，高肿瘤分期、阳性淋巴结和高 MALAT1 表达是膀胱癌患者总生存期（OS）的独立预后因素。qRT-PCR 显示，膀胱癌组织中 MALAT1 的表达是相邻正常组织的 2.85 倍（P <.001）。非肌层浸润性膀胱癌中 MALAT1 的表达为 2.673 ± 0.254，肌层浸润性膀胱癌中 MALAT1 的表达为 2.987 ± 0.381（P =.018）。在淋巴结阳性的膀胱癌标本中，MALAT1 的表达为 3.167 ± 0.297，而在淋巴结阴性的膀胱癌标本中，MALAT1 的表达为 2.896 ± 0.329（P =.020）。
高 MALAT1 表达可作为膀胱癌患者 OS 的独立预后因素，可作为膀胱癌潜在的治疗靶点。
